Sarcomatrix Advances Lead Compound S-969 to Large Animal Studies for Muscular Dystrophy
RENO, NV, UNITED STATES, May 13, 2024 /EINPresswire.com/ -- Sarcomatrix, a pioneering company in the development of innovative treatments for muscular dystrophies and other genetic disorders, proudly announces the advancement of its lead compound …